Global Geniculate Ganglionitis Drugs Market Size, Forecast, and Trend Highlights Over 2025-2037
Geniculate Ganglionitis Drugs Market size was valued at USD 320.5 million in 2024 and is projected to reach USD 720.3 million by the end of 2037, rising at a CAGR of 7.1% during the forecast period i.e. 2025-2037. In 2025, the industry size of geniculate ganglionitis drugs is evaluated at USD 342.1 million.
According to NIH, the annual occurrences of geniculate ganglionitis (GG) ranged between 120,010 and 150,004 around the world till 2024. This population is magnifying due to the significant influence of rising incidences of herpes zoster infections & immune dysfunctions, and advances in diagnostic capabilities. In this regard, WHO reported that immune disruptions originating from the COVID-19 surge increased the epidemiology of herpes zoster infections by 15.3% from 2022 to 2023. This demography describes the surge for reliable treatments, fueling the market. The heightening demand can further be testified by the report from the International Trade Council (ITC), which calculated the annual worldwide trade value of associated medicines and APIs to be USD 280.5 million in 2023.
The payers’ pricing of the final production output from the market depends on several factors, including tariff rates, manufacturing & marketing tax & incentives, API supply chain-related expenses, and logistics. Additionally, the procurement of regulatory compliance also affects the overall pricing strategy. For instance, during the timeline between 2023 and 2024, the producer price index (PPI) for these medications increased by a 4.4% year-on-year (YoY) rate, as per the U.S. Bureau of Labor Statistics (BLS). Simultaneously, the consumer price index (CPI) for involved treatments in this category rose by 6.0% throughout the same tenure (Centers for Medicare & Medicaid Services). High formulary prices in hospitals and retail pharmacies also stimulated this growth rate.
